xRead - Olfactory Disorders (September 2023)

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

571

PATEL et al.

TABLE IX-16 Evidence for AR-related olfactory loss management with intranasal topical corticosteroid therapy Study Year LOE Study design Study groups Clinical end point

Conclusions Compared with

SS-TDI

MixedAR(n = 47) MP-AZE/FP NS twice daily for 3 months Seasonal AR (n = 30) Montelukast and MF NS (n = 10) Montelukast (n = 10) MFNS (n = 10)

Klimeck et al 231

2017 3

Prospective

baseline, there was significant improvement in OF baseline, group 1 and 3 (those with MF) demonstrated significant improvement in SS-TDI improvement in SS-TDI in the montelukast group alone Limited evidence that topical steroids improve sense of smell Compared with No significant mometasone NS did not demonstrate significant benefit baseline, there was no significant improvement in either group difference between the 2 treatment arms mometasone group demonstrated significant improvement in chemosensory specific QOL but notUPSIT R Compared with No significant Compared with baseline, the mometasone group demonstrated significantly greater improvement on SS test (butanol) Compared with placebo, Compared with placebo, the

multicenter observational

Dalgic

2017 2

RCT

SS-TDI

et al 1367

Stuck

UPSIT R VAS Symptom score

2015 1

Systematic review Mixed AR

et al 225

5 RCTs and 1 cohort study

CCCRC olfactory test Chemosensory specific QOL SS-TDI

Higaki

2012 2

RCT

Seasonal AR MFNS Placebo

Questionnaire

et al 1436

Kalpaklioglu et al 1433

Symptom score

2010 2

RCT

MixedAR(n = 70) AZENS Tramcinolone NS

Sivam

2010 2

RCT

MixedAR(n = 17) MFNS Placebo

Chemosensory-specific QOLscore UPSIT R

et al 236

SS-TDI

Stuck

2003 2

RCT

Seasonal AR (n = 24) MFNS Placebo

et al 1368

(Continues)